CClinicalTrials.gg
WithdrawnNCT02384174Updated Jul 27, 2020

Resistant Starch and Non-starch Polysaccharide (Dietary Fibre) Intake and the Colonic Microbiome in Older People

An interventional study of Resistant starch and Dietary fibre (arabinogalactan, gum guar, pectin) in Aging, sponsored by University of Dundee. Withdrawn at 1 site in United Kingdom. Open to participants aged 70 Years to 95 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-07-27.

Sponsored by University of Dundee · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
70 Years to 95 Years
Sex
All
01

Study summary

The development of preventative nutritional strategies to promote healthy ageing is becoming increasingly important. Elevated thresholds for taste and smell, coupled with swallowing difficulties and masticatory dysfunction, often result in nutritionally imbalanced diets among the elderly. This can induce great changes in the composition and metabolic activities of the gut microbiome, leading to decreased intestinal motility and impaired bowel function. This can result in constipation or diarrhoea, increased basal levels of inflammation, immunosenescence and morbidity. The objectives of this study are to use dietary modification to improve gut health in older people. Diets high in resistant starch or dietary fibre will be given to 50 elderly volunteers (70-95 years) living in the community, in a randomised double-blind cross-over study. The aim is to investigate the effects on microbiome composition and functionality through fermentation, reduced putrefaction, and modification of blood markers associated with obesity and diabetes.

02

Conditions studied

  • Aging

Keywords

  • Aging
  • Resistant starch
  • Dietary fibre
  • Immune system
  • Bacteria
  • older subjects
03

In context

Lead sponsor

University of Dundee is the lead sponsor of 111 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
70 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Men and women aged 70-95 years, with BMI 18.5-30.0 kg m2.

Exclusion criteria

Exclusion Criteria:

  • Exclusion criteria will include asplenia and other acquired or congenital immunodeficiencies
  • Any autoimmune disease
  • Self-reported symptoms of acute or recent infection (including use of antibiotics within the previous 3 months)
  • Taking probiotics or prebiotics, including lactulose for constipation
  • Chronic gastrointestinal problems (e.g. Inflammatory Bowel Disease, Irritable Bowel Syndrome, cancer).
  • Specifically, volunteers who are diabetic will not be excluded from the investigation.
  • Assessment will be on a case by case basis.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Resistant starch (RS)

    Resistant starch (RS3)

    Dietary Supplement: Resistant starch

  • Experimental
    Dietary fibre

    Dietary fibre (Arabinogalactan, gum guar, pectin)

    Dietary Supplement: Dietary fibre (arabinogalactan, gum guar, pectin)

Interventions

  • Dietary supplementResistant starch
  • Dietary supplementDietary fibre (arabinogalactan, gum guar, pectin)
06

What researchers measure

Primary outcomes

  1. Number of participants with change in levels of faecal bifidobacteria measured by quantitative fluorescent in situ hybridisation (FISH).

    Time frame: 4 weeks

Secondary outcomes

  1. Number of participants with change in the bacterial composition of the faecal microbiome measured by quantitative FISH.

    Time frame: 4 weeks

  2. Number of participants with change in inflammatory markers linked to ageing measured in whole blood by enzyme linked immunosorbent assay (ELISA).

    Measurement of cytokines Interleukin 6 (IL-6), Tumour necrosis factor-alpha (TNF-alpha), IL-1, IL-10, Interferon-gamma (INF-gamma), IL-4, IL-8, Monocyte chemoattractant protein 1( MCP-1) and serum C-reactive protein (CRP).

    Time frame: 4 weeks

  3. Number of participants with change in faecal genotoxic potential determined by measurement of faecal bacterial enzymes involved in the formation of genotoxic metabolites in the gut.

    Enzymes to be measured beta-glucosidase, beta-glucuronidase, azoreductase, nitroreductase

    Time frame: 4 weeks

  4. Number of participants with a change in bowel habit and quality of life measured by completion of a bowel habit diary and quality of life questionnaire.

    Time frame: 4 weeks

07

Study locations

1 site
  • Division of Cardiovascular and Diabetes Medicine/Gastroenterology, Ninewells Hospital and Medical School
    Dundee, Tayside DD1 9SY, United Kingdom
08

References and documents

Publications

  • Woodmansey EJ, McMurdo ME, Macfarlane GT, Macfarlane S. Comparison of compositions and metabolic activities of fecal microbiotas in young adults and in antibiotic-treated and non-antibiotic-treated elderly subjects. Appl Environ Microbiol. 2004 Oct;70(10):6113-22. doi: 10.1128/AEM.70.10.6113-6122.2004. PubMed 15466557 ↗
  • Bartosch S, Fite A, Macfarlane GT, McMurdo ME. Characterization of bacterial communities in feces from healthy elderly volunteers and hospitalized elderly patients by using real-time PCR and effects of antibiotic treatment on the fecal microbiota. Appl Environ Microbiol. 2004 Jun;70(6):3575-81. doi: 10.1128/AEM.70.6.3575-3581.2004. PubMed 15184159 ↗
  • Macfarlane S, Cleary S, Bahrami B, Reynolds N, Macfarlane GT. Synbiotic consumption changes the metabolism and composition of the gut microbiota in older people and modifies inflammatory processes: a randomised, double-blind, placebo-controlled crossover study. Aliment Pharmacol Ther. 2013 Oct;38(7):804-16. doi: 10.1111/apt.12453. Epub 2013 Aug 20. PubMed 23957631 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 27, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02384174
Lead sponsor
University of Dundee
Collaborators
Chief Scientist Office of the Scottish Government
Responsible party
Sponsor
First posted
Mar 10, 2015
Start date
May 2015
Primary completion
Jan 2017 (estimated)
Completion
Feb 1, 2017
Last update
Jul 27, 2020

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion